FDA 483 - AstraZeneca Pharmaceuticals LP - March 19, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of AstraZeneca Pharmaceuticals LP Frederick Manufacturing Center revealed significant deficiencies across its operations. The firm failed to ensure the quality control unit's responsibilities were fully followed, including issues with electronic system validation and supplier material testing. Additionally, the facility demonstrated inadequate microbial control in drug substance manufacturing and failed to conduct thorough investigations into deviations and out-of-specification results.
ID · b308dbbf-6bee-4596-8859-b6320002a2e9